Mark Harvey said -
"We found some time ago that there was a Class Phenomenon for suicidal ideation and acts which meant that, together with other notable problems both in science and in law, successful litigation was unlikely. That was a decision I had to make irrespective of my personal concerns about these drugs and their links with suicidal ideation. It is noteworthy however that the original MHRA, EMEA and FDA investigations of SSRIs arose as a direct result of the focus on Seroxat and Paxil by the litigators both here and in the US and the media. That focus has highlighted the class issue. "
No comments:
Post a Comment
Note: only a member of this blog may post a comment.